VAL.L

ValiRx plc [VAL.L] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

VAL.L Stock Summary

Top 10 Correlated ETFs

VAL.L

Top 10 Correlated Stocks

VAL.L

In the News

VAL.L Financial details

Company Rating
-
Market Cap
4.83M
Income
-4.18M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
03 Jun 2024
P/E
-1.83
Forward P/E
-
PEG
-0.15
P/S
-
P/B
1.09
P/C
-
P/FCF
-4.41
Quick Ratio
8.92
Current Ratio
11.48
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.05
EPS next Y
-
EPS next Q
-
EPS this Y
30.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-33.12%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-61%
ROE
-63%
ROC
-0.67%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.4-15.0
52W High
-96.33%
52W Low
-81.67%
RSI
51
Rel Volume
0.43
Avg Volume
669.66K
Volume
289.15K
Perf Week
-8.33%
Perf Month
0%
Perf Quarter
-31.25%
Perf Half Y
-18.52%
-
-
-
-
Beta
0.632
-
-
Volatility
0.03%, 0.06%
Prev Close
0%
Price
0.55
Change
3.77%

Something similar

Top by Market Cap
NVDA
CMC.DE
VTI
ABEC.DE
V
Top Correlated ETFs
XUKS.L
TINF.L
TING.L
SUK2.L
TI5G.L
Top Correlated Stocks
4951.T
1518.T
PROC.L
HSW.L
4064.T
Similar Market Cap
GLIF
MLBBO.PA
LSLT
9077.HK
FWDB

Company Profile

Healthcare Biotechnology
  • Volume Average 669.66K
  • Market Capitalization 4.83M
  • Employee 8
  • CEO Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D.
  • Headquarters Hatfield,GB
  • IPO Date 2002-01-07
  • Website https://www.valirx.com

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.